Supernus Pharmaceuticals (SUPN) Downgraded by Zacks Investment Research

Zacks Investment Research downgraded shares of Supernus Pharmaceuticals (NASDAQ:SUPN) from a buy rating to a hold rating in a research note issued to investors on Friday.

According to Zacks, “Supernus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. It is developing several product candidates in neurology and psychiatry to address opportunities in epilepsy and attention deficit hyperactivity disorder. Supernus Pharmaceuticals Inc. is based in Rockville, Maryland. “

Other analysts have also issued research reports about the company. Cowen reaffirmed a buy rating and set a $50.00 price objective on shares of Supernus Pharmaceuticals in a research note on Thursday, September 21st. Jefferies Group reaffirmed a buy rating and set a $51.00 price objective on shares of Supernus Pharmaceuticals in a research note on Wednesday, September 20th. FBR & Co started coverage on Supernus Pharmaceuticals in a research note on Thursday, October 19th. They set a buy rating and a $53.00 price objective on the stock. Cantor Fitzgerald reaffirmed a buy rating and set a $49.00 price objective on shares of Supernus Pharmaceuticals in a research note on Wednesday, September 27th. Finally, Stifel Nicolaus raised Supernus Pharmaceuticals from a hold rating to a buy rating and set a $47.00 price objective on the stock in a research note on Tuesday, November 7th. Three analysts have rated the stock with a hold rating, eight have given a buy rating and one has given a strong buy rating to the company. The company presently has an average rating of Buy and a consensus target price of $49.90.

Shares of Supernus Pharmaceuticals (SUPN) opened at $44.15 on Friday. The firm has a market capitalization of $2,260.00, a price-to-earnings ratio of 40.14 and a beta of 1.17. Supernus Pharmaceuticals has a twelve month low of $23.10 and a twelve month high of $50.04.

Supernus Pharmaceuticals (NASDAQ:SUPN) last posted its earnings results on Monday, November 6th. The specialty pharmaceutical company reported $0.29 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.27 by $0.02. The company had revenue of $80.40 million for the quarter, compared to analyst estimates of $78.74 million. Supernus Pharmaceuticals had a return on equity of 26.37% and a net margin of 20.98%. The business’s revenue for the quarter was up 41.5% compared to the same quarter last year. research analysts anticipate that Supernus Pharmaceuticals will post 1.07 earnings per share for the current fiscal year.

In other Supernus Pharmaceuticals news, VP Victor Vaughn sold 15,000 shares of the firm’s stock in a transaction dated Tuesday, January 9th. The stock was sold at an average price of $42.04, for a total value of $630,600.00. Following the sale, the vice president now directly owns 24,344 shares of the company’s stock, valued at approximately $1,023,421.76. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CFO Gregory S. Patrick sold 50,000 shares of the firm’s stock in a transaction dated Thursday, January 11th. The stock was sold at an average price of $43.56, for a total value of $2,178,000.00. The disclosure for this sale can be found here. Over the last three months, insiders sold 120,000 shares of company stock worth $5,014,650. 6.70% of the stock is owned by corporate insiders.

A number of large investors have recently modified their holdings of SUPN. Vanguard Group Inc. boosted its stake in Supernus Pharmaceuticals by 39.1% in the 2nd quarter. Vanguard Group Inc. now owns 3,500,535 shares of the specialty pharmaceutical company’s stock worth $150,873,000 after buying an additional 984,200 shares during the last quarter. Pictet Asset Management Ltd. boosted its stake in Supernus Pharmaceuticals by 438.7% in the 3rd quarter. Pictet Asset Management Ltd. now owns 491,283 shares of the specialty pharmaceutical company’s stock worth $19,651,000 after buying an additional 400,083 shares during the last quarter. Scout Investments Inc. boosted its stake in Supernus Pharmaceuticals by 239.5% in the 3rd quarter. Scout Investments Inc. now owns 565,900 shares of the specialty pharmaceutical company’s stock worth $22,636,000 after buying an additional 399,225 shares during the last quarter. Janus Henderson Group PLC acquired a new stake in Supernus Pharmaceuticals in the 3rd quarter worth about $10,646,000. Finally, Royal Bank of Canada boosted its stake in Supernus Pharmaceuticals by 790.8% in the 2nd quarter. Royal Bank of Canada now owns 271,451 shares of the specialty pharmaceutical company’s stock worth $11,699,000 after buying an additional 240,978 shares during the last quarter. 98.22% of the stock is currently owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION WARNING: “Supernus Pharmaceuticals (SUPN) Downgraded by Zacks Investment Research” was reported by Transcript Daily and is the property of of Transcript Daily. If you are accessing this news story on another publication, it was illegally copied and reposted in violation of international trademark & copyright laws. The original version of this news story can be read at https://transcriptdaily.com/2018/01/16/supernus-pharmaceuticals-supn-downgraded-by-zacks-investment-research.html.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy.

Get a free copy of the Zacks research report on Supernus Pharmaceuticals (SUPN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Supernus Pharmaceuticals (NASDAQ:SUPN)

Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply